The co-delivery of a low-dose P-glycoprotein inhibitor with doxorubicin sterically stabilized liposomes against breast cancer with low P-glycoprotein expression
Wei Gao,1 Zhiqiang Lin,1 Meiwan Chen,2 Xiucong Yang,1 Zheng Cui,1 Xiaofei Zhang,1 Lan Yuan,3 Qiang Zhang11State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, 2State Key Laboratory of Quality Research in Chinese Medicine, Inst...
Guardado en:
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2014
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/5a6c244b6af4481891fd44023cc6a07e |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:5a6c244b6af4481891fd44023cc6a07e |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:5a6c244b6af4481891fd44023cc6a07e2021-12-02T06:30:31ZThe co-delivery of a low-dose P-glycoprotein inhibitor with doxorubicin sterically stabilized liposomes against breast cancer with low P-glycoprotein expression1178-2013https://doaj.org/article/5a6c244b6af4481891fd44023cc6a07e2014-07-01T00:00:00Zhttp://www.dovepress.com/the-co-delivery-of-a-low-dose-p-glycoprotein-inhibitor-with-doxorubici-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013 Wei Gao,1 Zhiqiang Lin,1 Meiwan Chen,2 Xiucong Yang,1 Zheng Cui,1 Xiaofei Zhang,1 Lan Yuan,3 Qiang Zhang11State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, 2State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, 3Medical and Healthy Analytical Center, Peking University, Beijing, People's Republic of China Introduction: P-glycoprotein (P-gp) inhibitors are usually used to treat tumors that overexpress P-gps. However, most common types of breast cancers, such as Luminal A, are low-P-gp expressing, at least during the initial phases of treatment. Therefore, it would be interesting to know if P-gp inhibitors are still useful in treating low-P-gp-expressing tumors. Methods: In the study reported here, the human breast-cancer cell line MCF-7, chosen as a model of Luminal A, was found to be low-P-gp expressing. We designed a novel doxorubicin (DOX) sterically stabilized liposome system co-loaded with the low-dose P-gp inhibitor cyclosporine A (CsA) (DOX/CsA/SSL). Results: The co-delivery system showed good size uniformity, high encapsulation efficiency, and a desirable release profile. The cell-uptake and cytotoxicity studies demonstrated that CsA could significantly enhance the intracellular accumulation and toxicity of free DOX and the liposomal DOX in MCF-7 cells. The confocal microscopy and in vivo imaging study confirmed the intracellular and in vivo targeting effect of DOX/CsA/SSL, respectively. Finally, the in vivo study proved that DOX/CsA/SSL could achieve significantly better antitumor effect against MCF-7 tumor than controls, without inducing obvious systemic toxicity. Conclusion: This study demonstrated that the co-delivery of a low-dose P-gp inhibitor and liposomal DOX could improve the therapy of low-P-gp-expressing cancer, which is of significance in clinical tumor therapy. Keywords: liposomes, low-P-gp-expressing tumor, antitumor activity, cyclosporine A, targeted deliveryGao WLin ZChen MYang XCui ZZhang XYuan LZhang QDove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2014, Iss Issue 1, Pp 3425-3437 (2014) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine (General) R5-920 |
| spellingShingle |
Medicine (General) R5-920 Gao W Lin Z Chen M Yang X Cui Z Zhang X Yuan L Zhang Q The co-delivery of a low-dose P-glycoprotein inhibitor with doxorubicin sterically stabilized liposomes against breast cancer with low P-glycoprotein expression |
| description |
Wei Gao,1 Zhiqiang Lin,1 Meiwan Chen,2 Xiucong Yang,1 Zheng Cui,1 Xiaofei Zhang,1 Lan Yuan,3 Qiang Zhang11State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, 2State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, 3Medical and Healthy Analytical Center, Peking University, Beijing, People's Republic of China Introduction: P-glycoprotein (P-gp) inhibitors are usually used to treat tumors that overexpress P-gps. However, most common types of breast cancers, such as Luminal A, are low-P-gp expressing, at least during the initial phases of treatment. Therefore, it would be interesting to know if P-gp inhibitors are still useful in treating low-P-gp-expressing tumors. Methods: In the study reported here, the human breast-cancer cell line MCF-7, chosen as a model of Luminal A, was found to be low-P-gp expressing. We designed a novel doxorubicin (DOX) sterically stabilized liposome system co-loaded with the low-dose P-gp inhibitor cyclosporine A (CsA) (DOX/CsA/SSL). Results: The co-delivery system showed good size uniformity, high encapsulation efficiency, and a desirable release profile. The cell-uptake and cytotoxicity studies demonstrated that CsA could significantly enhance the intracellular accumulation and toxicity of free DOX and the liposomal DOX in MCF-7 cells. The confocal microscopy and in vivo imaging study confirmed the intracellular and in vivo targeting effect of DOX/CsA/SSL, respectively. Finally, the in vivo study proved that DOX/CsA/SSL could achieve significantly better antitumor effect against MCF-7 tumor than controls, without inducing obvious systemic toxicity. Conclusion: This study demonstrated that the co-delivery of a low-dose P-gp inhibitor and liposomal DOX could improve the therapy of low-P-gp-expressing cancer, which is of significance in clinical tumor therapy. Keywords: liposomes, low-P-gp-expressing tumor, antitumor activity, cyclosporine A, targeted delivery |
| format |
article |
| author |
Gao W Lin Z Chen M Yang X Cui Z Zhang X Yuan L Zhang Q |
| author_facet |
Gao W Lin Z Chen M Yang X Cui Z Zhang X Yuan L Zhang Q |
| author_sort |
Gao W |
| title |
The co-delivery of a low-dose P-glycoprotein inhibitor with doxorubicin sterically stabilized liposomes against breast cancer with low P-glycoprotein expression |
| title_short |
The co-delivery of a low-dose P-glycoprotein inhibitor with doxorubicin sterically stabilized liposomes against breast cancer with low P-glycoprotein expression |
| title_full |
The co-delivery of a low-dose P-glycoprotein inhibitor with doxorubicin sterically stabilized liposomes against breast cancer with low P-glycoprotein expression |
| title_fullStr |
The co-delivery of a low-dose P-glycoprotein inhibitor with doxorubicin sterically stabilized liposomes against breast cancer with low P-glycoprotein expression |
| title_full_unstemmed |
The co-delivery of a low-dose P-glycoprotein inhibitor with doxorubicin sterically stabilized liposomes against breast cancer with low P-glycoprotein expression |
| title_sort |
co-delivery of a low-dose p-glycoprotein inhibitor with doxorubicin sterically stabilized liposomes against breast cancer with low p-glycoprotein expression |
| publisher |
Dove Medical Press |
| publishDate |
2014 |
| url |
https://doaj.org/article/5a6c244b6af4481891fd44023cc6a07e |
| work_keys_str_mv |
AT gaow thecodeliveryofalowdosepglycoproteininhibitorwithdoxorubicinstericallystabilizedliposomesagainstbreastcancerwithlowpglycoproteinexpression AT linz thecodeliveryofalowdosepglycoproteininhibitorwithdoxorubicinstericallystabilizedliposomesagainstbreastcancerwithlowpglycoproteinexpression AT chenm thecodeliveryofalowdosepglycoproteininhibitorwithdoxorubicinstericallystabilizedliposomesagainstbreastcancerwithlowpglycoproteinexpression AT yangx thecodeliveryofalowdosepglycoproteininhibitorwithdoxorubicinstericallystabilizedliposomesagainstbreastcancerwithlowpglycoproteinexpression AT cuiz thecodeliveryofalowdosepglycoproteininhibitorwithdoxorubicinstericallystabilizedliposomesagainstbreastcancerwithlowpglycoproteinexpression AT zhangx thecodeliveryofalowdosepglycoproteininhibitorwithdoxorubicinstericallystabilizedliposomesagainstbreastcancerwithlowpglycoproteinexpression AT yuanl thecodeliveryofalowdosepglycoproteininhibitorwithdoxorubicinstericallystabilizedliposomesagainstbreastcancerwithlowpglycoproteinexpression AT zhangq thecodeliveryofalowdosepglycoproteininhibitorwithdoxorubicinstericallystabilizedliposomesagainstbreastcancerwithlowpglycoproteinexpression AT gaow codeliveryofalowdosepglycoproteininhibitorwithdoxorubicinstericallystabilizedliposomesagainstbreastcancerwithlowpglycoproteinexpression AT linz codeliveryofalowdosepglycoproteininhibitorwithdoxorubicinstericallystabilizedliposomesagainstbreastcancerwithlowpglycoproteinexpression AT chenm codeliveryofalowdosepglycoproteininhibitorwithdoxorubicinstericallystabilizedliposomesagainstbreastcancerwithlowpglycoproteinexpression AT yangx codeliveryofalowdosepglycoproteininhibitorwithdoxorubicinstericallystabilizedliposomesagainstbreastcancerwithlowpglycoproteinexpression AT cuiz codeliveryofalowdosepglycoproteininhibitorwithdoxorubicinstericallystabilizedliposomesagainstbreastcancerwithlowpglycoproteinexpression AT zhangx codeliveryofalowdosepglycoproteininhibitorwithdoxorubicinstericallystabilizedliposomesagainstbreastcancerwithlowpglycoproteinexpression AT yuanl codeliveryofalowdosepglycoproteininhibitorwithdoxorubicinstericallystabilizedliposomesagainstbreastcancerwithlowpglycoproteinexpression AT zhangq codeliveryofalowdosepglycoproteininhibitorwithdoxorubicinstericallystabilizedliposomesagainstbreastcancerwithlowpglycoproteinexpression |
| _version_ |
1718399870511874048 |